Cantor Fitzgerald Predicts MREO FY2025 Earnings

Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Mereo BioPharma Group in a report released on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings of ($0.08) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $7.00 price target on the stock. The consensus estimate for Mereo BioPharma Group's current full-year earnings is ($0.03) per share.

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by ($0.03).

A number of other equities analysts have also weighed in on the stock. Jefferies Financial Group started coverage on shares of Mereo BioPharma Group in a research report on Friday, December 6th. They issued a "buy" rating and a $7.00 price objective for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a research note on Wednesday, March 26th. JPMorgan Chase & Co. began coverage on Mereo BioPharma Group in a report on Thursday, March 27th. They issued an "overweight" rating and a $7.00 price target for the company. Finally, Lifesci Capital began coverage on Mereo BioPharma Group in a report on Tuesday, December 24th. They set an "outperform" rating and a $10.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Mereo BioPharma Group presently has an average rating of "Buy" and an average price target of $7.71.

Remove Ads

Mereo BioPharma Group Stock Performance

MREO stock traded down $0.16 during trading on Monday, hitting $2.21. The stock had a trading volume of 1,187,376 shares, compared to its average volume of 1,015,438. The stock has a market cap of $342.87 million, a price-to-earnings ratio of -36.83 and a beta of 0.71. The company's 50 day moving average price is $2.66 and its two-hundred day moving average price is $3.43. Mereo BioPharma Group has a 1-year low of $2.11 and a 1-year high of $5.02.

Hedge Funds Weigh In On Mereo BioPharma Group

Hedge funds have recently made changes to their positions in the stock. Newbridge Financial Services Group Inc. acquired a new stake in shares of Mereo BioPharma Group during the 4th quarter worth $37,000. Jump Financial LLC purchased a new stake in Mereo BioPharma Group during the fourth quarter valued at about $39,000. Sheets Smith Investment Management purchased a new stake in Mereo BioPharma Group during the fourth quarter valued at about $59,000. Virtus ETF Advisers LLC acquired a new stake in Mereo BioPharma Group during the fourth quarter worth about $67,000. Finally, Avanza Fonder AB purchased a new position in shares of Mereo BioPharma Group in the 4th quarter worth about $69,000. Institutional investors and hedge funds own 62.83% of the company's stock.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.